Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777.
A link to the prescribing information can be found in the header.
Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex) is indicated for symptomatic treatment of focal spasticity of:
- Dynamic equinus foot deformity in ambulant paediatric cerebral palsy patients, two years of age or older
- Upper limbs in paediatric cerebral palsy patients, two years of age or older.
Please click here to see the full therapeutic indications.
CLIMB Online
Paediatric Spasticity
Dysport® Injection Handbook
A reference guide to the adminstration of Dysport for the treatment of paediatric spasticity, including the identification of muscles using ultrasound, and the recommended injection technique per muscle.
DYS-UK-008780
Dysport® Dose Map for Paediatric Spasticity
A reference guide to the dosing of Dysport® for the treatment of paediatric spasticity.
DYS-UK-008779
Dysport® Dilution Guide
A reference guide to reconstituting and diluting Dysport®
DYS-UK-008776
Dysport® Reconstitution Guide
7 minutes
How to prepare, reconstitute and store Dysport®
DYS-UK-008719
Overview of Paediatric Spasticity – eLearning Module
20 minutes
An overview of spasticity in children, including the classification of cerebral palsy and its consequences.
DYS-UK-008458
Goal Setting for Children with Spasticity
30 minutes
An overview of goal setting for children with spasticity including the Canadian Occupation Performance Measure (COPM) and Goal Attainment Scaling (GAS).
DYS-UK-008484
Dysport® Clinical Trial Data – eLearning Module
45 minutes
An overview of the phase 3 clinical studies of Dysport® in children with upper and lower limb spasticity
DYS-UK-008945
BoNT Immunogenicity: The difference between neutralising and non-neutralising antibodies
3 minutes
Understand the difference between neutralising and non-neutralising antibodies and how this difference should be considered during clinical decision-making.
DYS-UK-008783
Demystifying the Clinical Relevance of BoNT Immunogenicity
5 minutes
Learn about the difference between neutralising and non-neutralising antibodies, and factors to consider when investigating non-response to BoNT treatment
Presented by: Dr Tim Harrower
DYS-UK-008723
Use of Dysport® in paediatric upper limb spasticity.
17 minutes
Presented by: Dr Nigar Dursun
DYS-UK-008475
Goal Setting in Spastic Paresis
30 minutes
Presented by: Dr Nigar Dursun
DYS-UK-008477
Evolving Patterns of Deformity in Cerebral Palsy
3 minutes
Presented by: Mr. Peter Sanderson
DYS-UK-008476
Dysport® Mechanism of Action
3 minutes
DYS-UK-008722
© IPSEN Ltd, 5th Floor The Point, 37 North Wharf Road, London, W2 1AF, United Kingdom. All rights reserved. DYS-UK-008915 | October 2024
